Dr. Michael Kinnaman, MMF Research Fellow, shares his research summary

Kinnaman_180523_06 (003).jpg

I am currently working in a lab that focuses on studying how cancer evolves, or changes and adapts over time, to a point where it spreads from the original site of disease to other organs in the body. My research specifically focuses on applying my lab's expertise to studying different types of pediatric sarcomas. I currently have two active projects studying cancer evolution in both osteosarcoma and rhabdomyosarcoma.

Osteosarcoma is the most common pediatric bone tumor and there have been no significant advances with regards to therapy or overall survival over the last three decades. There are approximately 400 new cases each year that arise in children and adolescents younger than 20 years of age. Unfortunately, only 20% of patients who present with or develop metastases will survive.

To help improve therapy and our understanding of osteosarcoma, my project's goal is to characterize the tumor cells that are resistant to our current therapy. These cells are the bad actors that we need to characterize in order to cure this disease. To do this we will be doing whole genome sequencing, which allows us to map out the entire genetic code of a cancer cell, on patients' tumor samples at different time points throughout treatment. We will then compare the genetic makeup of each sample to the samples collected from earlier in a patient's treatment to see how the tumor has changed. This will allow us to not only identify the resistant tumor cells but also characterize and describe their genetic makeup. We hope this new information will lead to new treatment and treatment strategies that are specifically targeted towards these resistant tumor cells, improving outcomes for our patients with osteosarcoma.

My other research project involves studying evolution in rhabdomyosarcoma (cancer that typically begins in muscle cells), which is the most common type of soft tissue sarcoma in children. Only about 70% of patients who are diagnosed with rhabdomyosarcoma will be cured, and outcomes for adolescent patients is significantly worse.

To help improve therapy and our understanding of rhabdomyosarcoma, we are studying tumor samples that were donated by two patients at MSKCC, who had unusually aggressive forms of this cancer and ultimately died from their disease. They both consented to have a research autopsy performed after they died, donating their tumor samples to the research community as their last wish. Similar to the osteosarcoma project, we will be using genomic sequencing on the samples that were acquired to explain why their cancers were so resistant to treatment. This sequencing information will allow us to construct a genetic timeline of how their tumors changed and evolved over time. We believe this information will be

critical in deepening our understanding of how to better treat this disease in the future and improve outcomes for future patients diagnosed with rhabdomyosarcoma. Future research directions in our lab will be directed at studying cancer evolution in translocation driven pediatric sarcomas such as Ewing's sarcoma and desmoplastic small round cell tumor.

Luke Weber and Cycle for Survival support MSKCC cancer research

Luke Weber and the Srebnick family, longtime friends of Margaux’s Miracle, are amazing partners and fellow supporters of Memorial-Sloan Kettering Cancer Center.

They organize “Team Luke” through Cycle for Survival to raise funds for childhood cancer research.

You can learn more and participate in the Miami location for Cycle for Survival by clicking here.

Luke Weber - Cycle for Survival.jpg

MMF welcomes our new research fellow, Dr. Michael Kinnaman

Kinnaman_180523_06 (003).jpg

We are honored and excited to welcome Michael Kinnaman, MD, as the Margaux’s Miracle Foundation Fellow for academic year 2018-2019.

In addition to being this year’s MMF Fellow, Michael also serves as Chief Fellow at Memorial Sloan-Kettering Cancer Center.

Michael received his Bachelor of Science degree from the University of Michigan in 2008. He received his Medical Degree at Stony Brook University School of Medicine in 2013, and then completed his residency in 2016 at Children’s Hospital at Montefiore, here in New York.

Michael is a rising star in the field, and he is in the midst of very exciting and important pediatric sarcoma research. 

You can read his research summary here.

Luncheon 2018

Many thanks to our guest speaker Dan Abrams of ABC News, Calvin Hughes of WPLG Miami, and our Man of the Year, Dr. Paul Meyers.

Luncheon_2018_invite.jpg
DanAbrams.jpg
ManDown98292J.jpg

2018 Announcements from Dr. Paul Meyers

2018 Announcements from Dr. Paul Meyers

This has been another exciting and productive year for research in the sarcomas of children and young adults. Let me highlight four major advances and approaches: 

  1. We have successfully begun a clinical trial of a radically new approach for the treatment of Ewing sarcoma. Dr. Jeffrey Toretsky has developed a compound which completely stops the growth of Ewing sarcoma in the laboratory. In collaboration with colleagues at MD Anderson and UCLA, we have now enrolled 20 patients in a clinical trial to test this compound in children. We are required by the FDA to proceed slowly to prove that it is safe, but we are now reaching the doses that should have a beneficial effect. We are extremely excited about the possibilities for this line of investigation. 

  2. We have designed a trial for newly diagnosed patients with Ewing sarcoma that incorporates into our initial therapy two new drugs that achieved a high rate of response in patients with recurrent Ewing sarcoma. Our preliminary data are showing that we have increased the probability for cure for children who present without metastatic disease to 95%, which is a dramatic increase over our historical results of 70%. 

  3. Working with MSKCC’s Dr. Nai-Kong Cheung and his colleagues, we have developed an antibiotic that can help to control metastases of osteosarcoma, the most common form of primary bone cancer in children and young adults. We have treated over 40 children and young adults with this antibody. The results are sufficiently exciting and a company has agreed to sponsor a Phase III front line trial for patients with osteosarcoma which will be led by MSKCC but will include the participation of partners at other major cancer centers around the US. 

  4. Dr. Neerav Shukla, another MSKCC pediatric oncologist, has focused research on the genomics of pediatric tumors including Ewing sarcoma. He has developed an extremely sensitive assay to test for the presence of a DNA sequence unique to the tumor in 40 patients with Ewing sarcoma and it has shown exciting promise as an early warning detector for tumor recurrence before it becomes detectible by scans or X-rays. His exciting work has been published in the Journal of Precision Oncology and led to a leadership role in the Children’s Oncology Group to extend this work nationwide.

So to all Margaux’s Miracle Foundation supporters, I urge you to help us continue these vital efforts to eradicate these deadly and rare cancers. I look forward to seeing you on March 5th. 

Luncheon 2017

Our deepest gratitude to our guest speaker and world-renowned writer Gloria Steinem, Dr. Paul Meyers, and our female student guests from the University of Miami.

Luncheon_2017_invite.jpg
GloriaSteinem.jpg
Gloria-Steinem-My-Life-on-the-Road.png